Literature DB >> 12040906

Histopathology of brain tissue from patients with infantile spasms.

Harry V Vinters1.   

Abstract

This chapter reviews the patterns of neuropathologic abnormality encountered in cortical resections performed for the treatment of infantile spasms (ISS) in the broader context of the larger "universe" of neuropathology seen in the central nervous system of infants with this syndrome as well as older children with intractable epilepsy. Although destructive lesions (encephalomalacia), Sturge-Weber-Dimitri syndrome, and even neoplasms can cause ISS, its most common neuropathologic substrate is cortical dysplasia (CD), representing the result of aberrant neuronal migration to the neocortex from the germinal matrix. Ways to recognize CD morphologically and assess its severity are reviewed, as are special stains and immunohistochemical methods that may be useful in confirming the diagnosis. The similarity and relationship between (sporadic) CD and tubers of tuberous sclerosis are discussed. Future potentially fruitful research directions aimed at refining the clinicopathologic analysis of the role of CD in ISS and epilepsies of older children are briefly considered.

Entities:  

Mesh:

Year:  2002        PMID: 12040906     DOI: 10.1016/s0074-7742(02)49007-1

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  3 in total

Review 1.  Infantile spasms: review of the literature and personal experience.

Authors:  Alberto Fois
Journal:  Ital J Pediatr       Date:  2010-02-08       Impact factor: 2.638

2.  Improved outcomes in pediatric epilepsy surgery: the UCLA experience, 1986-2008.

Authors:  M Hemb; T R Velasco; M S Parnes; J Y Wu; J T Lerner; J H Matsumoto; S Yudovin; W D Shields; R Sankar; N Salamon; H V Vinters; G W Mathern
Journal:  Neurology       Date:  2010-04-28       Impact factor: 9.910

Review 3.  Cortical dysplasia: neuropathological aspects.

Authors:  Christian H Rickert
Journal:  Childs Nerv Syst       Date:  2006-06-09       Impact factor: 1.475

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.